First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA).
暂无分享，去创建一个
N. Schultz | C. Chong | D. Solit | F. Sánchez-Vega | Y. Janjigian | G. Ku | J. Hechtman | M. Capanu | H. Gerdes | D. Kelsen | D. Ilson | J. Chou | M. Shcherba | Pari M. Shah | Brittanie M Millang | E. Won | P. Momtaz | M. Simmons | Kathrena Aljallad | M. Segal | Michal Segal